FDA 483 - Patrick Clarke, M.D. - May 01, 2021

An FDA inspection of Patrick Clarke, M.D. in Los Angeles revealed significant deficiencies in the conduct of a clinical study. The firm failed to adhere to the investigational plan and protocol, including not reporting adverse events and numerous protocol deviations. These issues indicate a lack of proper oversight and execution during the clinical trial.